Sun Pharma, Aurobindo in focus after US tariff exemption
In short
Sun Pharma, Aurobindo Pharma and other Indian drug stocks moved into focus after the US exempted India and 19 other countries from 100% tariffs on some patented specialty drugs. The exemption covers rare-disease drugs, gene and cell therapies, and infertility treatments.
This may help companies that sell those products. Generic medicines are still outside the tariffs, but the exact impact on earnings was not stated.
What the reporting says
Sun Pharma, Aurobindo Pharma and other Indian pharma stocks were in focus after the US exempted India and 19 other countries from 100% tariffs on certain patented specialty pharmaceuticals and ingredients. The publisher summary says the exemption covers rare-disease drugs, gene and cell therapies, and infertility treatments, while generic medicines remain outside the Section 232 tariffs. The immediate implication is relief for some specialty-drug exporters, but the size of any earnings impact is unknown.
Why it matters
The US exempted India and 19 other countries from 100% tariffs on certain patented specialty pharmaceuticals and ingredients, putting Sun Pharma, Aurobindo Pharma and peers in focus. The reported exemption includes rare-disease drugs, gene and cell therapies, and infertility treatments. Generic medicines remain outside the Section 232 tariffs, but the reporting does not quantify the financial benefit.